Hetvi Bharadia

Hetvi Bharadia

Auto-generated profile, based on publicly available information

Hetvi Bharadia

Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Ahmedabad, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Journal of Drug Targeting
Verified
Journal Article
Closed access
AKAvinash Khadela
Avinash Khadela
KMKashvy R. Morakhia
Kashvy R. Morakhia
NSNishra H. Shah
Nishra H. Shah
VKVibha G. Kanjani
Vibha G. Kanjani
VSVraj B. Shah
Vraj B. Shah
MMManthan Merja
Manthan Merja
Human epidermal growth factor 2-negative breast cancer (HER2-BC) is characterized by the lack of HER2 amplification and encompasses triple-negative breast cancer and hormone receptor-positive HER2-negative breast cancer. Triple-negative breast cancer is distinguished by a total lack of estrogen and progesterone receptors, along with the lack of HER2 amplification. While hormone receptor-positive HER2-negative breast cancer is marked by expression of estrogen receptors with or without progesterone receptors. The major drawback of triple-negative breast cancer is the lack of an enforceable biomarker, and that of hormone receptor-positive HER2-negative breast cancer is endocrine therapy resistance. Consequently, these therapeutic failures result in relapse/recurrence, disease progression, and ultimately a poor prognosis. Sacituzumab govitecan is a novel 3rd generation antibody-drug conjugate that selectively blocks trophoblast cell-surface antigen-2, a highly expressed protein in HER2-BC. This review elaborates on the shortcomings of the standard therapeutic regimens in HER2-BC and the role of Sacituzumab govitecan in addressing these limitations. Clinical trials proposing its application in locally advanced HER2-BC have also been included. Furthermore, clinical trials showcasing the combination of Sacituzumab govitecan with numerous therapeutic modalities improving patient survival and quality of life in metastatic disease have also been included in the text.

6 August 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
HBHetvi Bharadia
Hetvi Bharadia
ADAkshada Dabhade
Akshada Dabhade
ASAayushi Chetankumar Shah
Aayushi Chetankumar Shah
RPRajanikant Patel
Rajanikant Patel
MCMehul R Chorawala
Mehul R Chorawala
PSPalak Shah
Palak Shah

29 May 2024 in Zeitschrift für Naturforschung C
Verified
Journal Article
Closed access
ASAayushi Chetankumar Shah
Aayushi Chetankumar Shah
ADAkshada Dabhade
Akshada Dabhade
HBHetvi Bharadia
Hetvi Bharadia
PPPriyajeet S. Parekh
Priyajeet S. Parekh
MYMayur R. Yadav
Mayur R. Yadav
MCMehul R Chorawala
Mehul R Chorawala
Theranostics refers to the combination of diagnostic biomarkers with therapeutic agents that share a specific target expressed by diseased cells and tissues. Nuclear medicine is an exciting component explored for its applicability in theranostic concepts in clinical and research investigations. Nuclear theranostics is based on the employment of radioactive compounds delivering ionizing radiation to diagnose and manage certain diseases employing binding with specifically expressed targets. In the realm of personalized medicine, nuclear theranostics stands as a beacon of potential, potentially revolutionizing disease management. Studies exploring the theranostic profile of radioactive compounds have been presented in this review along with a detailed explanation of radioactive compounds and their theranostic applicability in several diseases. It furnishes insights into their applicability across diverse diseases, elucidating the intricate interplay between these compounds and disease pathologies. Light is shed on the important milestones of nuclear theranostics beginning with radioiodine therapy in thyroid carcinomas, MIBG labelled with iodine in neuroblastoma, and several others. Our perspectives have been put forth regarding the most important theranostic agents along with emerging trends and prospects.